Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) is a clinical-stage biopharmaceutical company focused on developing cancer therapies. This Form 10-Q covers the quarterly period ended June 30, 2024. The company's two lead product candidates are revumenib (a menin inhibitor for acute leukemias) and axatilimab (an anti-CSF-1R antibody for chronic graft-versus-host disease and idiopathic pulmonary fibrosis). The company has no approved products for commercial sale and has not generated product revenue to date.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Total Revenue | $3.5 million | $3.5 million | N/A |
| Net Loss | $(68.1) million | $(140.5) million | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.80) | $(1.65) | N/A |
| Operating Expenses | $77.7 million | $157.2 million | N/A |
| Cash, Cash Equivalents & Investments | N/A | N/A | $454.6 million |
| Accumulated Deficit | N/A | N/A | $(1.04) billion |
Revenue Composition: The $3.5 million in revenue for the quarter and six-month period was derived entirely from milestone and license revenue related to the achievement of milestones under a license agreement with Eddingpharm Investment Company Limited regarding entinostat approval in China.
Expense Breakdown (Six Months): Research and Development (R&D) expenses were $105.1 million, and Selling, General, and Administrative (SG&A) expenses were $52.1 million.
Material Changes vs. Prior Period
- Revenue: Increased from $0 in the prior year periods to $3.5 million due to the Eddingpharm milestone achievement.
- Net Loss: Widened significantly. The net loss for the six months ended June 30, 2024, was $140.5 million compared to $85.7 million in the same period in 2023 (a 64% increase).
- R&D Expenses: Increased by 53% year-over-year for the six-month period ($105.1 million vs. $68.8 million). This was driven by increased costs for revumenib registrational trials, preparation for combination trials, and pre-commercial manufacturing.
- SG&A Expenses: Increased by 94% year-over-year for the six-month period ($52.1 million vs. $26.9 million). This increase is primarily attributed to commercial readiness activities in anticipation of regulatory approvals and increased headcount.
- Liquidity: Cash, cash equivalents, and short- and long-term investments decreased from $612.9 million at December 31, 2023, to $476.9 million in total assets (with $454.6 million in liquid investments) as of June 30, 2024, reflecting operating cash burn.
Guidance, Outlook, and Risks
Regulatory Milestones:
- Revumenib: The New Drug Application (NDA) for relapsed/refractory KMT2A-rearranged acute leukemia is under FDA Priority Review. The PDUFA target action date was extended from September 26, 2024, to December 26, 2024.
- Axatilimab: The Biologics License Application (BLA) for chronic graft-versus-host disease (cGVHD) is under FDA Priority Review with a PDUFA action date of August 28, 2024.
Outlook: Management expects to report topline data from the AUGMENT-101 pivotal trial cohort for revumenib in mNPM1 AML in the fourth quarter of 2024. The company anticipates continuing to incur significant losses for the foreseeable future as it advances clinical development and prepares for commercialization.
Liquidity: As of June 30, 2024, the company had $454.6 million in cash and investments. Management believes this is sufficient to fund projected operating expenses and capital requirements for at least the next 12 months.
Risks: Key risks include the uncertainty of regulatory approvals for revumenib and axatilimab, the potential for clinical trial delays or failures, reliance on third-party manufacturers and collaborators (specifically Incyte for axatilimab), and the need for additional capital to fund operations beyond the next 12 months.
Investor Verification Checklist
- Regulatory Decisions: Monitor the FDA's decision on the axatilimab BLA (PDUFA date: August 28, 2024) and the revumenib NDA (PDUFA date: December 26, 2024).
- Cash Burn Rate: Verify the sustainability of the $454.6 million cash position against the current quarterly burn rate of approximately $70 million in net loss.
- Clinical Data: Await the release of topline data from the AUGMENT-101 trial for revumenib in mNPM1 AML, expected in Q4 2024.
- Collaboration Status: Review the status of the collaboration with Incyte Corporation regarding the development and commercialization of axatilimab.
- Commercial Readiness: Assess the company's ability to scale SG&A expenses effectively if regulatory approvals are granted, given the 94% year-over-year increase in these costs.